Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Spyre Therapeutics (...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Spyre Therapeutics, with a price target of $116.00. Slutsky...

Spyre Therapeutics (SYRE) Gets a Buy from LifeSci Capital

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Solventum Corporation (SOLV), Argenx Se (ARGX) and S...

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)

Spyre Therapeutics ($SYRE) fell as much as 14% in after‑hours trading on Tuesday after the company said it will stop developing its rheumatoid arth...

Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Spyre Therapeutics, with a price target of $129.00. Slutsky...

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS P...

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

Wedbush analyst David Nierengarten maintained a Buy rating on Spyre Therapeutics today and set a price target of $130.00. Nierengarten covers the H...

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tv...

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Revolution Medicines (...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SYRE	$88.98	+1.98%	803.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SYRE	$88.98	+2.0%	803.86K
3
4
5
6

SYRE

Get Spyre Therapeutics, Inc. Data in Excel

Get Spyre Therapeutics, Inc. Data in Excel